170 related articles for article (PubMed ID: 35134369)
1. Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study.
Abtahi S; Cordtz R; Dreyer L; Driessen JHM; Boonen A; Burden AM
Am J Med; 2022 Jul; 135(7):879-888.e3. PubMed ID: 35134369
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway.
Tronstad I; Hoff M; Horn J; Vikjord SAA; Videm V; Johansson J; Nilsen TIL; Langhammer A
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38382944
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
[TBL] [Abstract][Full Text] [Related]
4. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study.
Dreyer L; Cordtz RL; Hansen IMJ; Kristensen LE; Hetland ML; Mellemkjaer L
Ann Rheum Dis; 2018 Apr; 77(4):510-514. PubMed ID: 29217620
[TBL] [Abstract][Full Text] [Related]
5. Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study.
Cordtz R; Mellemkjær L; Glintborg B; Hetland ML; Madsen OR; Jensen Hansen IM; Dreyer L
Rheumatology (Oxford); 2016 Jun; 55(6):1017-22. PubMed ID: 26912584
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
7. Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.
Roussy JP; Bessette L; Bernatsky S; Rahme E; Lachaine J
Osteoporos Int; 2013 Sep; 24(9):2483-92. PubMed ID: 23504029
[TBL] [Abstract][Full Text] [Related]
8. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
[TBL] [Abstract][Full Text] [Related]
9. Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers.
Cordtz RL; Hawley S; Prieto-Alhambra D; Højgaard P; Zobbe K; Overgaard S; Odgaard A; Kristensen LE; Dreyer L
Ann Rheum Dis; 2018 May; 77(5):684-689. PubMed ID: 29247125
[TBL] [Abstract][Full Text] [Related]
10. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
[TBL] [Abstract][Full Text] [Related]
11. Medications associated with fracture risk in patients with rheumatoid arthritis.
Ozen G; Pedro S; Wolfe F; Michaud K
Ann Rheum Dis; 2019 Aug; 78(8):1041-1047. PubMed ID: 31092411
[TBL] [Abstract][Full Text] [Related]
12. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
13. Association between biologic therapy and fracture incidence in patients with selected rheumatic and autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
Lv F; Hu S; Lin C; Cai X; Zhu X; Ji L
Pharmacol Res; 2022 Jul; 181():106278. PubMed ID: 35644324
[TBL] [Abstract][Full Text] [Related]
14. Impact of biologic disease-modifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: a systematic review and meta-analysis.
Shao F; Li HC; Wang MJ; Cui CM
Eur Rev Med Pharmacol Sci; 2021 May; 25(9):3416-3424. PubMed ID: 34002814
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of osteoporotic fractures in Swedish patients with rheumatoid arthritis despite early treatment with potent disease-modifying anti-rheumatic drugs: a prospective general population-matched cohort study.
Nyhäll-Wåhlin BM; Ajeganova S; Petersson IF; Andersson M
Scand J Rheumatol; 2019 Nov; 48(6):431-438. PubMed ID: 31322028
[No Abstract] [Full Text] [Related]
16. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying antirheumatic drugs and risk of thyroxine-treated autoimmune thyroid disease in patients with rheumatoid arthritis.
Waldenlind K; Delcoigne B; Saevarsdottir S; Askling J
J Intern Med; 2024 Mar; 295(3):313-321. PubMed ID: 37990795
[TBL] [Abstract][Full Text] [Related]
18. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
[TBL] [Abstract][Full Text] [Related]
19. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
20. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
